Biopharma's least novel indications

Oncology is by far the most popular segment for novel drug development. But what about the less active areas of biopharma? The analysis below shows the number of NMEs, both marketed and clinical-stage, for each EvaluatePharma indication group, excluding those in oncology. A closer look at those indications less well served by novel therapeutics reveals a mix of classes either with a well-established generic market, or where effective targets remain elusive to the biopharma world. For our analysis of cancer's novel projects see: Oncology's haves and have-nots, July 22, 2019.

Source: EvaluatePharma Vision*; data from July 2019.

*This story has been updated to reflect the change of name from EvaluatePharma Vision to Omnium Risk